AIM To investigate the utility of hepatitis B surface antigen (HBsAg) kinetics in chronic
hepatitis B patients during long-term entecavir treatment. METHODS This retrospective study …

Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and
association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving …

OBJECTIVES: The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients
receiving oral antiviral therapy is controversial. We aimed to determine the HBsAg response …

Results Twenty-eight patients were treated for a median period of 21 months (range: 18 to
24 mo). Serum HBsAg level showed a mean of 4.0, 3.7, and 3.6 log 10 IU/mL at …

Background & Aims We investigated the rate of relapse of hepatitis B virus (HBV) infection
after entecavir therapy for chronic hepatitis B and the association between level of hepatitis …

The aim of this study was to investigate the on‐treatment kinetics of quantitative HBsAg
during entecavir therapy to predict the treatment period needed to achieve functional cure …

Methods This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years,
mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; …

Background/purpose The study compared the hepatitis B surface antigen (HBsAg) changes
between hepatitis B e antigen (HBeAg)-negative non-cirrhotic chronic hepatitis B patients …

Background The clinical value of quantitative hepatitis B surface antigen (qHBsAg) titre in
patients taking nucleotide/nucleoside analogues (NAs) is still controversial. This study aims …

Background: The ultimate goal of hepatitis B treatment is hepatitis B surface antigen
(HBsAg) seroclearance. Several factors have been suggested to be associated with the rate …